Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9999369
Laser-scribed ferrogel sensor with magnetic particles
granted -
US 9994910
Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
granted -
US 9994814
Method for cellular restoration
granted -
US 9993553
Methods and compositions for targeted release of molecules from nanoscale carriers
granted -
US 9993642
Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
granted -
US 9993503
Methods for production of platelets from pluripotent stem cells and compositions thereof
granted -
US 9993537
Methods and compositions related to Th-1 dendritic cells
granted -
US 9993437
Mesoporous silica nanoparticles for biomedical applications
granted -
US 9993440
Enzyme responsive nanocapsules for protein delivery
granted -
US 9994901
Pro-inflammatory mediators in diagnosis and treatment of chronic obstructive pulmonary disease
granted -
US 9988602
Methods for producing enucleated erythroid cells derived from pluripotent stem cells
granted -
US 9987211
Sunless tanning compounds and compositions
granted -
US 9988603
Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
granted -
US 9988371
Benzimidazole analogues and related methods
granted -
US 9987363
Materials with water-triggered drug-release properties for localized therapeutics
granted -
US 9987346
Methods and compositions for vaccinating a subject for a sexually transmitted pathogen
granted -
US 9987261
Substituted diazaspiroalkanes as androgen receptor modulators
granted -
US 9987241
Enzyme conjugate and prodrug cancer therapy
granted -
US 9986723
Screen and use of therapeutics for pancreatic ductal adenocarcinoma
granted -
US 9982356
Membrane template synthesis of microtube engines
granted -
US 9982265
Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
granted -
US 9981961
Deoxycytidine kinase inhibitors
granted -
US 9981067
Biomimetic hybrid gel compositions and methods of use
granted -
US 9981043
Analgesic conjugates
granted -
US 9981034
Compositions and methods for vaccination against influenza A virus
granted -
US 9980943
Methods of treating muscular dystrophy
granted -
US 9980936
BH4 antagonists and methods related thereto
granted -
US 9980924
Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
granted -
US 9980634
Minimally-invasive measurement of esophageal inflammation
granted -
US 9980956
Methods and therapeutic combinations for treating tumors
granted -
US 9982260
Identification of structurally similar small molecules that enhance therapeutic exon skipping
granted -
US 9974844
Cancer vaccine compositions and methods of using the same
granted -
US 9976123
Cellular seeding and co-culture of a three dimensional fibroblast construct
granted -
US 9977021
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ tregs
granted -
US 9976115
Bone marrow adipose portion isolation device and methods
granted -
US 9974866
Protein-poly(2-oxazoline) conjugates for enhanced cellular delivery and transport across biological barriers
granted -
US 9974850
Immunogenic compositions and uses thereof
granted -
US 9974828
Isoform nell-1 peptide
granted -
US 9975959
Administration of kynurenine depleting enzymes for tumor therapy
granted -
US 9977033
Methods for assessing cancer recurrence
granted -
US 9970037
Methods and materials for making simvastatin and related compounds
granted -
US 9969970
DNA-cell conjugates
granted -
US 9969804
Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin
granted -
US 9968664
Fusion molecule based on novel TAA variant
granted -
US 9969803
Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof
granted -
US 9968638
Compositions and methods for transplantation of colon microbiota
granted -
US 9962352
Creatine oral supplementation using creatine hydrochloride salt
granted -
US 9962432
Minimizing intestinal dysfunction
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory